The FMHR traders and Stephanie Link of TIAA Global Asset Management, take their positions on stocks in earnings news, including Procter & Gamble's turnaround story. » Read More
The Dow gives up a 200-point gain as traders second guess the Fed decision. Fast Money offers some clarity on the future - as well as a ton of after-hours action - in the Word on the Street.
abstract goes here
Eli Lilly posted a higher fourth-quarter profit Tuesday. The pharmaceutical firm cited lower taxes and better-than-expected drug sales -- especially sales of its newer formulations for diabetes and cancer. John Lechleiter, president and chief operating officer -- and Lilly's CEO as of April 1 -- gave CNBC his strong earnings outlook.
Direct-to-consumer pharmaceutical advertising is everywhere in American media because it works. Generally speaking, it drives patients to ask/tell their doctors to prescribe a particular medication.
Eli Lilly Tuesday said fourth-quarter profit rose on lower taxes and better-than-expected sales of its medicines, including its newer treatments for depression, diabetes and cancer.
Despite recent market upheavals, Sidney Taurel, CEO of Eli Lilly, says he is not convinced the pharmaceuticals sector will be negatively impacted. “The pharmaceutical industry is not that affected by business cycles, and so I believe this financial and possible economic crisis isn’t going to affect significantly our company or the industry.”
The show was over, but Cramer kept going. Don't miss his in-depth answers to audience questions about Merck, Target and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
For the second time this week, big pharma is taking a beating from critical reports about medications. This time, it's antidepressants. But one analyst thinks the drag on shares is overdone -- and names "exciting" pharma stocks.
If or when you watch one of the presidential debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...
In the wake of Pfizer pulling the plug on its poor-selling inhaled insulin Exubera, the world's biggest diabetes drug company, Novo Nordisk is throwing in the towel on development of its version of inhaled insulin.
Even though I'm back on the East Coast today I wanted to share what I think is an interesting anecdote from my time Monday at the JPMorgan Healthcare Conference which is wrapping up in San Francisco.
BioMed Tracker, which closely monitors the clinical trial and drug approval process for investors, is out with a new report today on the Food and Drug Administration's record last year. The drug approval rate went down 13 percent and the number of "approvable letters" went up a whopping 40 percent. An approvable letter has become a euphemism for "delay."
Eli Lilly Tuesday said U.S. regulators approved once-daily use of two low-dose forms of its Cialis anti-impotence drug, offering greater convenience for men expecting frequent sexual activity.
Alcoa (AA) kicks off earnings season Wednesday after the bell. Which stocks and sectors look the best?
Slowdown talk hurts tech, commodities, defense stocks today. UBS downgrades IBM on concerns about a slowing in tech orders; Deutsche Bank downgrades Boeing and Goodrich. Commodities weak across the board—metals, steel, iron ore (2nd day in a row.) Defensive stocks—consumer, drugs all strong. Lilly upgraded at Morgan Stanley.
Stocks rebounded to close mixed amid worries over the economy and geopolitical tensions.
Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.
You’ve probably noticed one of the many scenic TV commercials that advertise prescription drugs. But did you notice what some of them are attempting to sell you?
Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.
Merry Christmas! The ECB's decision to inject half a trillion (trillion!) into the global marketplace (technically, they are providing what is essentially unlimited loans at a fixed fate for the next couple weeks) is definitely giving equities a shot in the arm this morning. This should put some pressure on bonds, lower LIBOR rates, and maybe prop up the dollar a bit.